Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults

11 oktober 2018 bijgewerkt door: AIDS Clinical Trials Group

A Pilot Efficacy and Safety Trial of Raltegravir Plus Darunavir/Ritonavir for Treatment-Naive HIV-1-Infected Subjects

The purpose of this study is to assess the effectiveness and safety of an antiretroviral therapy (ART) regimen consisting of raltegravir (RAL) and darunavir (DRV)/ritonavir (RTV) as first-line therapy in treatment-naïve participants.

Studie Overzicht

Toestand

Voltooid

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Despite the remarkable strides made in the treatment of HIV-1-infected persons over the last decade, current first-line ART regimens are imperfect. The ideal combination, unlike some current first-line options, would have uncompromised efficacy in the presence of transmitted drug-resistant variants. The primary purpose of this study is to estimate the cumulative proportion of ART-naive participants experiencing virologic failure at or prior to week 24 after initiating raltegravir (RAL) plus darunavir/ritonavir (DRV/RTV).

The study will last 52 weeks. All participants will follow the same treatment schedule and take RAL plus DRV/RTV orally daily for the duration of the trial.

After entry, all participants will have scheduled visits at weeks 1, 4, 12, 24, 36, 48, and 52. Medical/medication history, blood and urine collection, and liver function tests will occur at screening. A targeted physical exam and concomitant medications history will occur at all study visits. Blood and urine collection and liver function tests will occur at most study visits. For females, a pregnancy test will occur at screening and study entry.

RAL and DRV were provided by the study. RTV was not provided by the study.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

113

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Verenigde Staten
    • Alabama
      • Birmingham, Alabama, Verenigde Staten, 35294
        • AlabamaTherapeutics CRS
    • California
      • Palo Alto, California, Verenigde Staten, 94304
        • Stanford CRS
      • San Diego, California, Verenigde Staten, 92103
        • Ucsd, Avrc Crs
      • San Francisco, California, Verenigde Staten, 94110
        • Ucsf Aids Crs
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
        • University of Colorado Hospital CRS
    • District of Columbia
      • Washington, District of Columbia, Verenigde Staten, 20007
        • Georgetown University CRS
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60611
        • Northwestern University CRS
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02115
        • Beth Israel Deaconess Med Center
      • Boston, Massachusetts, Verenigde Staten, 02115
        • Brigham and Women's Hosp. ACTG CRS
    • Missouri
      • Saint Louis, Missouri, Verenigde Staten, 63110
        • Washington U CRS
    • New York
      • Rochester, New York, Verenigde Staten, 14604
        • AIDS Community Health Ctr. ACTG CRS
    • North Carolina
      • Chapel Hill, North Carolina, Verenigde Staten, 27599
        • Unc Aids Crs
      • Durham, North Carolina, Verenigde Staten, 27710
        • Duke Univ. Med. Ctr. Adult CRS
    • Ohio
      • Cincinnati, Ohio, Verenigde Staten, 45267-0405
        • Univ. of Cincinnati CRS
      • Cleveland, Ohio, Verenigde Staten, 44106
        • Case CRS
      • Cleveland, Ohio, Verenigde Staten, 44109
        • MetroHealth CRS
      • Columbus, Ohio, Verenigde Staten, 43210
        • The Ohio State Univ. AIDS CRS
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104
        • Hosp. of the Univ. of Pennsylvania CRS
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15213
        • University of Pittsburgh CTU
    • Rhode Island
      • Providence, Rhode Island, Verenigde Staten, 02906
        • The Miriam Hospital
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37203
        • Vanderbilt Therapeutics CRS
    • Texas
      • Houston, Texas, Verenigde Staten, 77030
        • Houston AIDS Research Team

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • HIV-1-infected
  • Plasma HIV-1 RNA of at least 5,000 copies/mL within 90 days prior to study entry
  • HIV genotype (for reverse transcriptase and protease) performed at any time prior to study entry. More information on this criterion can be found in the protocol.
  • ARV drug-naive. More information on this criterion can be found in the protocol.
  • Negative result from a hepatitis B surface antigen test performed within 90 days prior to study entry
  • Agree to use one form of medically-accepted contraceptive throughout the study and for 60 days after stopping study treatment. More information on this criterion can be found in the protocol.

Exclusion Criteria:

  • Serious illness requiring systemic treatment and/or hospitalization for at least 7 days prior to study. More information on this criterion can be found in the protocol.
  • Screening HIV genotype obtained any time prior to study entry with more than one DRV resistance-associated mutation [RAM] (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, I84V, and L89V) or L76V alone
  • Known major integrase inhibitor RAM(s), including N155H, Q148H/R/K, Y143C/R, and G140S
  • Severe renal insufficiency requiring hemodialysis or peritoneal dialysis
  • Treatment with immunomodulators within 30 days prior to study entry. More information on this criterion can be found in the protocol.
  • Current medications that are prohibited with any study medications. More information on this criterion can be found in the protocol.
  • Known allergy/sensitivity to study drugs or their formulations. A history of sulfa allergy is not an exclusion.
  • Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with the study.
  • Certain abnormal laboratory results. More information on this criterion can be found in the protocol.
  • Pregnant or breastfeeding

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: RAL + DRV/RTV
Raltegravir (400 mg BID) plus Darunavir/Ritonavir (800 mg/100 mg QD) for 52 weeks
Geneesmiddel: Raltegravir
400 mg tablet taken orally twice daily
Andere namen:
  • RAL
Geneesmiddel: Darunavir/Ritonavir
800 mg Darunavir/100 mg Ritonavir tablet taken orally once daily
Andere namen:
  • DRV/RTV

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of Participants With Virologic Failure After Initiating RAL Plus DRV/RTV at or Prior to Week 24
Tijdsspanne: From start of study treatment to week 24
Virologic failure is defined as: at week 12, confirmed plasma HIV-1 RNA >= 1000 copies/ml or confirmed rebound from the week 4 value by >0.5 log10 copies/ml (for subjects with week 4 value <= 50 copies/ml, confirmed rebound to >50 copies/ml); at week 24 or later, confirmed value > 50 copies/ml. Viral load confirmation was scheduled 7-35 days after initial virologic failure. The proportion was estimated using Kaplan-Meier method. An adaptation of Greenwood's variance estimate was used in constructing the confidence interval.
From start of study treatment to week 24

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of Participants With Virologic Failure or Off Study Treatment Regimen or Death at or Prior to Week 24
Tijdsspanne: From start of study treatment to Week 24
The proportion of participants with virologic failure (see primary outcome measure for definition) and/or premature treatment discontinuation/modification and/or death was estimated using Kaplan-Meier method. An adaptation of Greenwood's variance estimate was used in constructing the confidence interval.
From start of study treatment to Week 24
Change in Plasma HIV-1 RNA From Baseline to Week 1
Tijdsspanne: Baseline and week 1
Results report the week 1 change from baseline (week 1 - baseline) in HIV-1 RNA. Baseline HIV-1 RNA was computed as the mean of the log10 HIV-1 RNA values at pre-entry and study entry.
Baseline and week 1
Proportion of Participants With Plasma HIV-1 RNA < 50 Copies/ml or <200 Copies/ml at Week 24
Tijdsspanne: From start of study treatment to week 24
Results report the percentage of participants with plasma HIV-1 RNA < 50 copies/ml or <200 copies/ml at week 24.
From start of study treatment to week 24
Proportion of Participants With Plasma HIV-1 RNA <50 Copies/ml or <200 Copies/ml at Week 48
Tijdsspanne: From start of study treatment to week 48
Results report the percentage of participants with plasma HIV-1 RNA <50 copies/ml or <200 copies/ml at week 48.
From start of study treatment to week 48
Proportion of Participants Who Experienced Signs/Symptoms or Laboratory Toxicities Grade 3 or Higher, or of Any Grade Which Led to a Permanent Change or Discontinuation of Study Treatment
Tijdsspanne: From start of study treatment to week 52
Signs, symptoms and laboratory values were graded according to the Division of AIDS Adverse Event Grading System. Results report the percentage of participants who had grade 3 or higher events, or events of any grade which led to a permanent change or discontinuation of study treatment, which occurred any time from start of treatment to end of treatment.
From start of study treatment to week 52
Number of Participants With Pretreatment Drug Resistance
Tijdsspanne: At screening
Results report the number of participants who had resistance to non-nucleoside reverse transciptase inhibitors (NNRTI), nucleoside reverse transciptase inhibitors (NRTI) and protease inbitors (PI) based on genotypic resistance testing done prior to participant's entry into the study. Participants are classified into one (and only one category) based on the maximum number of drug class resistance seen for the participant.
At screening
Number of Participants With Integrase Drug Resistance at Virologic Failure
Tijdsspanne: From 12 weeks after starting study treatment to week 52
Results report the number of participants who had integrase resistance mutation(s) detected at the time of virologic failure.
From 12 weeks after starting study treatment to week 52
Number of Participants With Protease Drug Resistance at Virologic Failure
Tijdsspanne: From 12 weeks after starting study treatment to week 52
Results report the number of participants who had protease resistance mutation(s) detected at the time of virologic failure.
From 12 weeks after starting study treatment to week 52
Number of Participants With Perfect Overall Adherence by Self Report
Tijdsspanne: From one week after starting study treatment to week 52
At each study visit, adherence was measured in terms of the number of missed doses each participant had over a 4-day recall for each drug. Adherence for all study visit weeks were combined for an overall measure of adherence. Participants who had zero missed doses on all weeks in all drugs while on study were classified as having an overall "perfect" adherence.
From one week after starting study treatment to week 52
Changes in Fasting Total Cholesterol, High-density Lipoprotein and Triglyceride at Week 24
Tijdsspanne: From start of study treatment through week 24
Results report the week 24 change from week 0 (week 24 - week 0) fasting total cholesterol, high-density lipoprotein and triglyceride.
From start of study treatment through week 24
Change in Fasting Low-density Lipoprotein at Week 24
Tijdsspanne: From start of study treatment through week 24
Results report the week 24 change from week 0 (week 24 - week 0) fasting low-density lipoprotein (LDL). For participants whose calculated fasting LDL and direct fasting LDL were both reported, only the calculated fasting LDL was used. Direct fasting LDL was reported when the participant had high fasting triglyceride.
From start of study treatment through week 24
Changes in Fasting Total Cholesterol, High-density Lipoprotein and Triglyceride at Week 48
Tijdsspanne: From start of study treatment through week 48
Results report the week 48 change from week 0 (week 48 - week 0) fasting total cholesterol, high-density lipoprotein and triglyceride.
From start of study treatment through week 48
Change in Fasting Low-density Lipoprotein at Week 48
Tijdsspanne: From start of study treatment through week 48
Results report the week 48 change from week 0 (week 48 - week 0) fasting low-density lipoprotein (LDL). For participants whose calculated fasting LDL and direct fasting LDL were both reported, only the calculated fasting LDL was used. Direct fasting LDL was reported when the participant had high fasting triglyceride.
From start of study treatment through week 48
Change in CD4 Count at Week 48
Tijdsspanne: From start of study treatment through week 48
Results report the week 48 change from baseline (week 48 - baseline) in CD4 count. Baseline CD4 count was computed as the mean of CD4 count values at pre-entry and study entry.
From start of study treatment through week 48
Plasma Trough Concentration of Raltegravir
Tijdsspanne: From start of study treatment to week 52
Plasma trough concentrations (ng/ml) of Raltegravir (RAL) below the detection limit (10 ng/ml) were replaced by half the corresponding lower limit of quantitation. Geometric mean of trough concentrations obtained within the prescribed trough time (within 9-15 hours after the last RAL dose) was computed for each participant. For participants who experienced virologic failure (see primary outcome measure definition), only those concentrations on or before virologic failure confirmation were used in the geometric mean computation.
From start of study treatment to week 52
Plasma Trough Concentration of Darunavir
Tijdsspanne: From start of study treatment to week 52
Plasma trough concentrations (ng/ml) of Darunavir (DRV) below the detection limit (50 ng/ml) were replaced by half the corresponding lower limit of quantitation. Geometric mean of trough concentrations obtained within the prescribed trough time (within 20-28 hours after the last DRV dose) was computed for each participant. For participants who experienced virologic failure (see primary outcome measure definition), only those concentrations on or before virologic failure confirmation were used in the geometric mean computation.
From start of study treatment to week 52

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

AIDS Clinical Trials Group

Medewerkers

National Institute of Allergy and Infectious Diseases (NIAID)

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 april 2009

Primaire voltooiing (Werkelijk)

1 februari 2010

Studie voltooiing (Werkelijk)

1 september 2010

Studieregistratiedata

Eerst ingediend

26 januari 2009

Eerst ingediend dat voldeed aan de QC-criteria

27 januari 2009

Eerst geplaatst (Schatting)

28 januari 2009

Updates van studierecords

Laatste update geplaatst (Werkelijk)

8 november 2018

Laatste update ingediend die voldeed aan QC-criteria

11 oktober 2018

Laatst geverifieerd

1 oktober 2018

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • ACTG A5262
  • 1U01AI068636 (Subsidie/contract van de Amerikaanse NIH)

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren